Pharmaceutical composition and administrations thereof

A pharmaceutical table comprising:

• a. a solid dispersion in an amount ranging from 30% to 50% by weight of the tablet, wherein the dispersion comprises:
• i) 80% of amorphous or substantially amorphous N-[2,4-Bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide (Compound 1) by weight of the dispersion, wherein substantially amorphous Compound 1 comprises less than 15% crystalline Compound 1,
• ii) 19.5% of hydroxypropylmethyl cellulose acetate succinate (HPMCAS) by weight of the dispersion, and
• iii) 0.5% of sodium lauryl sulfate (SLS) by weight of the dispersion;
• b. a filler, in an amount ranging from 25% to 50% by weight of the tablet;
• c. a disintegrant, in an amount ranging from 1% to 10% by weight of the tablet;
• d. a surfactant, in an amount ranging from 0.3% to 2% by weight of the tablet;
• e. a binder, in an amount ranging from 20% to 45% by weight of the tablet;
• f. a glidant, in an amount ranging from 0.09% to 1.0% by weight of the tablet;
• and
• g. a lubricant, in an amount ranging from 0.1% to 2% by weight of the tablet.